Ralph Niven - 14 Dec 2021 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
Chief Development Officer
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
14 Dec 2021
Net transactions value
$0
Form type
4
Filing time
16 Dec 2021, 17:00:10 UTC
Previous filing
29 Jun 2021
Next filing
19 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Award $0 +65,433 $0.000000 65,433 14 Dec 2021 Common Stock 65,433 $10.61 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on January 14, 2022.